Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Receivables Refunds (2020 - 2022)

Nurix Therapeutics (NRIX) has disclosed Receivables Refunds for 3 consecutive years, with $204000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Receivables Refunds fell 94.88% to $204000.0 in Q1 2022 year-over-year; TTM through Feb 2022 was $204000.0, a 94.88% decrease, with the full-year FY2021 number at $204000.0, down 94.7% from a year prior.
  • Receivables Refunds was $204000.0 for Q1 2022 at Nurix Therapeutics, roughly flat from $204000.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $4.0 million in Q1 2021 to a low of $204000.0 in Q3 2021.
  • A 3-year average of $2.2 million and a median of $3.1 million in 2021 define the central range for Receivables Refunds.
  • Peak YoY movement for Receivables Refunds: tumbled 94.7% in 2021, then tumbled 94.88% in 2022.
  • Nurix Therapeutics' Receivables Refunds stood at $3.8 million in 2020, then crashed by 94.7% to $204000.0 in 2021, then changed by 0.0% to $204000.0 in 2022.
  • Per Business Quant, the three most recent readings for NRIX's Receivables Refunds are $204000.0 (Q1 2022), $204000.0 (Q4 2021), and $204000.0 (Q3 2021).